Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

BACKGROUND Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown. METHODS We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estimated glomerular filtration rate [GFR], 15 to <30 ml per minute per 1.73 m(2) of body-surface area) to bardoxolone methyl, at a daily dose of 20 mg, or placebo. The primary composite outcome was end-stage renal disease (ESRD) or death from cardiovascular causes. RESULTS The sponsor and the steering committee terminated the trial on the recommendation of the independent data and safety monitoring committee; the median follow-up was 9 months. A total of 69 of 1088 patients (6%) randomly assigned to bardoxolone methyl and 69 of 1097 (6%) randomly assigned to placebo had a primary composite outcome (hazard ratio in the bardoxolone methyl group vs. the placebo group, 0.98; 95% confidence interval [CI], 0.70 to 1.37; P=0.92). In the bardoxolone methyl group, ESRD developed in 43 patients, and 27 patients died from cardiovascular causes; in the placebo group, ESRD developed in 51 patients, and 19 patients died from cardiovascular causes. A total of 96 patients in the bardoxolone methyl group were hospitalized for heart failure or died from heart failure, as compared with 55 in the placebo group (hazard ratio, 1.83; 95% CI, 1.32 to 2.55; P<0.001). Estimated GFR, blood pressure, and the urinary albumin-to-creatinine ratio increased significantly and body weight decreased significantly in the bardoxolone methyl group, as compared with the placebo group. CONCLUSIONS Among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, bardoxolone methyl did not reduce the risk of ESRD or death from cardiovascular causes. A higher rate of cardiovascular events with bardoxolone methyl than with placebo prompted termination of the trial. (Funded by Reata Pharmaceuticals; BEACON ClinicalTrials.gov number, NCT01351675.).

[1]  John P A Ioannidis,et al.  Improving the drug development process: more not less randomized trials. , 2014, JAMA.

[2]  K. Tuttle,et al.  Novel therapies for diabetic kidney disease. , 2013, Advances in chronic kidney disease.

[3]  D. Zeeuw The End of Dual Therapy with Renin–Angiotensin–Aldosterone System Blockade? , 2013 .

[4]  P. Peduzzi,et al.  Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.

[5]  J. McMurray,et al.  Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  Ambuj Kumar,et al.  Medical research: Trial unpredictability yields predictable therapy gains , 2013, Nature.

[7]  K. Ward,et al.  Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity. , 2013, American journal of physiology. Renal physiology.

[8]  G. Remuzzi,et al.  Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. , 2013, American journal of physiology. Renal physiology.

[9]  J. McMurray,et al.  Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) , 2013, American Journal of Nephrology.

[10]  N. Vaziri,et al.  Targeting the Transcription Factor Nrf2 to Ameliorate Oxidative Stress and Inflammation in Chronic Kidney Disease , 2012, Kidney international.

[11]  Nish Chaturvedi,et al.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[12]  S. Lazic,et al.  A call for transparent reporting to optimize the predictive value of preclinical research , 2012, Nature.

[13]  K. Ward,et al.  Bardoxolone methyl decreases megalin and activates nrf2 in the kidney. , 2012, Journal of the American Society of Nephrology : JASN.

[14]  D. Arnold,et al.  Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. , 2012, The New England journal of medicine.

[15]  David H. Miller,et al.  Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. , 2012, The New England journal of medicine.

[16]  G. Braden Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy , 2012 .

[17]  Philip Raskin,et al.  Bardoxolone methyl and kidney function in CKD with type 2 diabetes. , 2011, The New England journal of medicine.

[18]  F. Collins Reengineering Translational Science: The Time Is Right , 2011, Science Translational Medicine.

[19]  D. Warnock,et al.  Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD , 2011, American Journal of Nephrology.

[20]  D. de Zeeuw,et al.  The kidney in type 2 diabetes therapy. , 2011, The review of diabetic studies : RDS.

[21]  P. Saha,et al.  The Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic-acid Methyl Ester Has Potent Anti-diabetic Effects in Diet-induced Diabetic Mice and Leprdb/db Mice* , 2010, The Journal of Biological Chemistry.

[22]  L. Ruilope,et al.  Avosentan for overt diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.

[23]  S. Solomon,et al.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.

[24]  J. Nunnelee Review of an article: The ADVANCE Collaborative Group. (2008). Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. NEJM 2008;358:2560-2572. , 2008 .

[25]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[26]  Kazuya Maeda,et al.  Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor , 2007, Drug Metabolism and Disposition.

[27]  V. Vollrath,et al.  Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene. , 2006, The Biochemical journal.

[28]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[29]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[30]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[31]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[32]  G. Beck,et al.  The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .

[33]  H. Parving,et al.  EARLY AGGRESSIVE ANTIHYPERTENSIVE TREATMENT REDUCES RATE OF DECLINE IN KIDNEY FUNCTION IN DIABETIC NEPHROPATHY , 1983, The Lancet.